瑞舒伐他汀钙对冠心病合并高脂血症患者血清hs-CRP及颈动脉内膜中层厚度的影响

目的:分析不同剂量瑞舒伐他汀钙治疗冠心病合并高脂血症患者的临床效果以及对患者血清hs-CRP和颈动脉内膜中层厚度(IMT)的影响。方法:选择2013年6月-2015年6月在我院接受治疗的冠心病合并高脂血症患者203例,根据用药剂量不同将其分为小剂量组(70例)、中剂量组(64例)及大剂量组(69例),分别采用口服瑞舒伐他汀钙5 mg/次/日、10 mg/次/日和20 mg/次/日进行治疗。观察并比较三组患者治疗前后血脂(TG,TC,LDL-C,HDL-C)、血清hs-CRP及IMT的变化情况。结果:治疗前,三组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值比较,差别均无统计学意义(P0.05);治疗后,三组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值均较治疗前降低,差异具有统计学意义(P0.05);大剂量瑞舒伐他汀钙组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值显著低于中剂量组和小剂量组,差异具有统计学意义(P0.05);中剂量组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值显著低于小剂量组,差异具有统计学意义(P0.05)。结论:瑞舒伐他汀钙能够改善冠心病合并高脂血症患者的血脂水平、降低血清hs-CRP及IMT,并且其疗效与药物剂量存在量效关系。

Effects of Rosuvastatin Calciumon the SerumLevels of hs-CRP and IMT of Patients with Coronary Heart Disease and Hyperlipidemia*

Objective:To analyze the clinical effect of different doses of rosuvastatin calcium on the treatment of coronary heart disease and hyperlipidemia and the influence on the serum hs-CRP and IMT.Methods:203 patients with coronary heart disease and hyperlipidemia who were treated in our hospital fromJune 2013 to June 2015 were selected and according to the different doses of rosuvastatin, the patients were divided into the small dose group (70 cases), the moderate dose group (64 cases) and the large dose group (69 cases), that were treated with oral administration of rosuvastatin calcium for 5 mg/ d, 10 mg/d and 20 mg/d, respectively. Then the changes of blood lipids (TC, LDL-C, TG, HDL-C), serum hs-CRP levels and IMT in the three groups were observed and compared before and after treatment.Results:groups before treatment (P>0.05); Compared with before treatment, the serumlevels of hs-CRP, TG, TC, LDL-C, HDL-C and IMT in the three groups decreased after treatment, and the differences were statistically significant (P<0.05); The serumlevels of hs-CRP, TG, TC, LDL-C, HDL-C and IMT of patients in large dose group were lower than those of the small dose group and the moderate dose group, and the differences were statistically significant (P<0.05); The serum levels of hs-CRP, TG, TC, LDL-C, HDL-C and IMT of patients in moderate dose group were lower than those of the small dose group, and the differences were statistically significant (P<0.05);Conclusion:Rosuvastatin can improve the blood lipids, decrease the serum levels of hs-CRP levels and IMT in patients with coronary heart disease and hyperlipidemia, which is worthy of clinical application.